Article -> Article Details

Market Overview

The global medical cyclotron market was valued at USD 247.5 Million in 2024 and is poised to reach USD 478.3 Million by 2033, growing at a CAGR of 7.22% during the forecast period of 2025-2033. Asia Pacific dominated the market in 2024, driven by rising cancer prevalence, advancements in radiopharmaceuticals, increasing demand for PET scans, expanding healthcare infrastructure, and supportive government initiatives. The market growth is further supported by technological innovations and growing research activities.

Study Assumption Years

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

Medical Cyclotron Market Key Takeaways

• The global medical cyclotron market size was USD 247.5 Million in 2024.
• The market is expected to grow at a CAGR of 7.22% between 2025 and 2033.
• The market size is forecasted to reach USD 478.3 Million by 2033.
• Asia Pacific dominated the market in 2024 due to healthcare infrastructure expansion, increasing cancer prevalence, and adoption of PET imaging.
• The rising demand for diagnostic imaging procedures, especially PET scans, is a key growth driver.
• Supportive government policies and increasing research activities promoting nuclear medicine and diagnostic imaging contribute significantly.
• Technological innovations have led to the development of compact and efficient cyclotrons facilitating decentralized isotope production.

Sample Request Link: https://www.imarcgroup.com/medical-cyclotron-market/requestsample

Market Growth Factors

1. Growing Need for Diagnostic Imaging and Rising Disease Rates

The medical cyclotron market is on the rise, driven by an ongoing surge in diagnostic imaging procedures, especially Positron Emission Tomography (PET) scans that rely on radioisotopes produced by cyclotrons. With the global uptick in cancer and cardiovascular diseases, the demand for accurate and early diagnosis has never been more critical. This need is pushing the adoption of cyclotron systems that generate vital isotopes for PET scans, which are essential for early disease detection and effective treatment evaluation.

2. Innovations in Radiopharmaceuticals and Nuclear Medicine

Recent breakthroughs in radiopharmaceuticals have greatly improved diagnostic and therapeutic uses in fields like oncology, cardiology, and neurology. The global radiopharmaceuticals market, which was valued at USD 5.8 billion in 2024, is expected to soar to USD 8.9 billion by 2033, growing at a compound annual growth rate (CAGR) of 4.9%. The incorporation of AI and machine learning into radiopharmaceutical research is paving the way for the development of new compounds, leading to a higher demand for various radioisotopes produced through medical cyclotrons.

3. Growing Healthcare Infrastructure and Supportive Government Policies

The expansion of healthcare infrastructure, particularly in emerging markets like India—boasting over 169,000 Sub-Centres along with numerous Primary Health Centres and hospitals—is significantly boosting the market. Investments in new PET and PET-CT facilities in hospitals and diagnostic clinics, along with government funding and policies aimed at improving access to advanced diagnostic tools and essential radiopharmaceuticals, are key drivers of sustained market growth. Supportive initiatives are fostering advancements in nuclear medicine and promoting decentralized isotope production.

Market Segmentation

Analysis by Type:

• Ring Cyclotron: Dominate the market due to their superior ability to produce high-energy radioisotopes required for advanced PET imaging. Their efficient and continuous acceleration delivers high yields of pure radioisotopes and supports diverse medical applications beyond oncology.
• Azimuthally Varying Field (AVF) Cyclotron

Analysis by Product Type:

• Cyclotron 16-18 MeV: Led the market in 2024 because of the optimal balance of production capacity and operational efficiency. Capable of producing Fluorine-18, essential for PET imaging, these cyclotrons offer sufficient yield, cost-effectiveness, and adaptability for various diagnostic and therapeutic applications.
• Cyclotron 10-12 MeV
• Cyclotron 19-24 MeV
• Cyclotron 24 MeV and Above

Analysis by End User:

• Hospitals: Lead the market with a key role in producing radioisotopes essential for PET and SPECT imaging. Hospitals benefit from in-house cyclotrons by reducing reliance on external suppliers, lowering costs, and enhancing nuclear medicine department efficiency.
• Diagnostic Centers
• Research and Academic Institutes
• Others

Regional Insights

Asia Pacific was the largest market in 2024, attributed to robust healthcare infrastructure expansion in countries such as China, Japan, and India. Growing government investments, expanding diagnostic infrastructure, and rising prevalence of cancer and chronic diseases contribute to the region’s dominance. The presence of leading cyclotron manufacturers and active R&D in nuclear medicine further bolster growth.

Recent Developments & News

• February 2025: The State Government of Nagpur announced plans to establish a cyclotron center to facilitate early cancer detection and nuclear research.
• February 2025: Framatome partnered with IBA (Ion Beam Applications S.A., EURONEXT) to industrially manufacture alpha-emitting radioisotope Astatine-211 in the US and Europe.
• November 2024: The National Institute of Science Education and Research (NISER), Bhubaneswar, revealed plans to start building a medical cyclotron facility for producing radioactive isotopes for PET CT and SPECT-CT scans.
• October 2024: The African Medical Centre of Excellence (AMCE) announced plans to establish a cyclotron facility in Abuja to support diagnosis and treatment of complex diseases.

Key Players

• Advanced Cyclotron Systems Inc.
• Alcen
• Best Medical International Inc.
• General Electric Company
• IBA RadioPharma Solutions
• Ionetix Corporation
• Isosolution Inc.
• Siemens AG
• Sumitomo Heavy Industries Ltd.
• Varian Medical Systems Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request For Customization:

https://www.imarcgroup.com/request?type=report&id=4573&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302